Using Scalable RNA Screening to Accelerate RNA-Targeted Drug Discovery

• Moving beyond case-by-case RNA discovery by developing scalable screening workflows that identify functional RNA structures and tractable targets earlier
• Comparing fragment-based, affinity-based, and cell-based screening approaches to determine which technologies generate actionable RNA-targeted hits
• Prioritizing functional output over binding alone to reduce false positives and identify compounds with meaningful RNA-modulating activity

Speakers:

Charlotte Henderson

Co-Founder & Chief Executive Officer

RevoNA Bio